




Recovering Hearts. Saving Lives.™

Q4 FY 2017 Earnings Call


Financial Results & Operational Highlights

FINANCIAL RESULTS, Q4 FY 2017


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




FINANCIAL RESULTS, ANNUALLY


Revenue (\$M) & Growth Rate




Cash (\$M)



Gross Margin %




Operating Margin %




U.S. UTILIZATION MIX, Q4 FY 2017

Revenue by Impella Device




Utilization by Indication*



Abiomed Revenue Growth:
33%

U.S. Patient Growth:
30%

Hospital Site Penetration



* Protected PCI patients are elective and urgent PCI patients. Emergent includes AMI cardiogenic shock, post-surgery shock and other shock.

ABIOMED FY 2018 GUIDANCE, AS OF MAY 4, 2017

Abiomed FY'18 Guidance

Revenue

\$555 – 575M ; 25 – 29%

Operating Margin %

22 - 24%